Is JOURNAVX (suzetrigine) a DEA‑controlled substance, and if so, what schedule is it in; is it a Schedule II narcotic?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

JOURNAVX (Suzetrigine) is NOT a DEA-Controlled Substance

JOURNAVX (suzetrigine) is not a DEA-controlled substance and has no schedule classification—it is not a Schedule II narcotic or any other scheduled drug. This represents a fundamental departure from traditional opioid analgesics used for acute pain management.

Regulatory Classification

Based on the FDA drug label 1, suzetrigine is approved as a non-scheduled medication for moderate to severe acute pain in adults. Unlike opioid analgesics that fall under DEA scheduling (Schedule II-IV), suzetrigine operates through a completely different mechanism—selective inhibition of the NaV1.8 voltage-gated sodium channel in peripheral sensory neurons 1.

Key Distinctions from Scheduled Opioids

Mechanism separates it from controlled substances:

  • Suzetrigine blocks peripheral pain signal transmission without crossing the blood-brain barrier 2, 3
  • No euphoric effects, respiratory depression, or addiction potential observed in clinical trials 4
  • Does not act on opioid receptors, distinguishing it from all Schedule II narcotics like morphine, oxycodone, and hydrocodone 5

Clinical implications of non-scheduled status:

  • No DEA registration or special prescribing requirements needed
  • No prescription limits on duration or refills beyond standard medical practice
  • No PDMP (Prescription Drug Monitoring Program) reporting requirements 6, 7
  • Can be prescribed by any licensed prescriber without special training or waivers (unlike buprenorphine for pain, which is Schedule III) 8

Comparison to Traditional Pain Management

For context, Schedule II opioids include morphine, oxycodone, hydromorphone, and fentanyl—all requiring strict DEA controls due to high abuse potential 5. Schedule III includes hydrocodone combinations and buprenorphine 5, 8. Suzetrigine's non-scheduled status reflects its novel mechanism and absence of abuse liability signals in clinical development 9, 10.

This represents the first new non-opioid analgesic class approved since celecoxib in 1998 3, offering an alternative that avoids the regulatory burden and addiction risks inherent to scheduled narcotics while providing comparable efficacy to hydrocodone/acetaminophen for acute pain 11, 12.

References

2
Research

Suzetrigine for Acute Pain in the Emergency Department: A First-in-Class NaV1.8 Blocker.

Journal of the American College of Emergency Physicians open, 2026

11
Research

The Clinical Application of Suzetrigine.

Journal of pain & palliative care pharmacotherapy, 2026

Related Questions

When should Journavax (suzetrigine) be administered relative to anesthesia, and what are the recommended dosing, timing, and contraindications for postoperative use?
What is the recommended dosing regimen for suzetrigine, including loading and maintenance doses, and how should it be adjusted for hepatic or renal impairment and CYP3A inhibitor interactions?
Is there evidence that Journavx (suzetrigine) is effective for treating chronic neuropathic pain due to syringomyelia in adults?
Is suzetrigine (Journavx) contraindicated in a patient with multiple sclerosis who has chronic low back pain from a vertebral fracture with sclerosis and neuropathy?
What is Suzetrigine (Journavx) indicated for?
At what minimum alveolar concentration (MAC) does stage 2 (excitation or delirium phase) typically occur?
What alternative antibiotic can be used instead of linezolid for methicillin‑resistant Staphylococcus aureus (MRSA) infection to avoid its hematologic and neurologic toxicities?
What is the recommended dosing, safety monitoring, and drug‑interaction considerations for tramadol in a kidney‑transplant recipient with stable graft function who needs moderate to severe pain control, especially when estimated glomerular filtration rate (eGFR) is below 30 mL/min?
How long does rabies virus remain infectious when exposed to sunlight (ultraviolet radiation) in open environments?
What is the appropriate management for a patient with fractional flow reserve (FFR) of 0.83 in the mid left anterior descending artery (LAD) and 0.80 in the proximal left anterior descending artery (LAD)?
Which neurotransmitters are involved in Tourette syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.